CoreCap Advisors’s Y-mAbs Therapeutics YMAB Stock Holding History

CoreCap Advisors’s Portfolio YMAB Stock Details YMAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-46	Closed	-$204	–	3288
2025 Q1	$204	Buy	+46	New	+$267	﹤0.01%	2973

Other funds holding YMAB

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

CoreCap Advisors's YMAB Position: Q2 2025 in Review

CoreCap Advisors sold out of Y-mAbs Therapeutics (YMAB) in Q2 2025, closing a stake of 46 shares — an estimated $204 sold.

CoreCap Advisors first reported a position in YMAB in Q1 2025 and held it in 1 quarter. The position peaked at $204 in Q1 2025. 97 funds tracked by Wall St. Rank hold YMAB as of Q2 2025.

CoreCap Advisors reported no remaining Y-mAbs Therapeutics position as of Q2 2025 after selling out during the quarter.
CoreCap Advisors sold 46 Y-mAbs Therapeutics shares in Q2 2025, an estimated $204.
CoreCap Advisors first reported a position in Y-mAbs Therapeutics in Q1 2025 and held it in 1 quarter.
CoreCap Advisors's Y-mAbs Therapeutics position peaked at $204 in Q1 2025.
97 funds tracked by Wall St. Rank held Y-mAbs Therapeutics as of Q2 2025.

Based on CoreCap Advisors's 13F filing for Q2 2025, filed 14 Aug 2025.